Guidance for Industry
Changes to an Approved Application
for Specified Biotechnology and
Specified Synthetic Biological Products
U.S. Department of Public Health
Food and Drug Administration
Center for Biologics Evaluation and Research
Center for Drug Evaluation and Research
July 1997  TABLE OF CONTENTS
Note: page numbering may vary for documents distributed electronically
I. INTRODUCTION 1
II. CHANGES UNDER 601.12(b) and 314.70(g)(1) 3
Changes requiring supplement submission and approval prior to
distribution of the product made using the change (major changes).
III. CHANGES UNDER 601.12(c) and 314.70(g)(2) 4
Changes requiring supplement submission at least 30 days
prior to distribution of the product made using the change.
IV. CHANGES UNDER 601.12(d) and 314.70(g)(3) 5
Changes to be described in an annual report (minor changes).
 
V. COMPARABILITY PROTOCOLS UNDER 601.12(e)  6
and 314.70(g)(4)
VI. CHANGES UNDER 601.12(f)  7
Labeling changes.
A. Changes under 601.12(f)(1) - Labeling changes requiring  7
supplement submission - FDA approval must be obtained
before distribution of the product with the labeling change.
B. Changes under 601.12(f)(2) - Labeling changes requiring  7
supplement submission - product with a labeling change
may be distributed before FDA approval.
C. Changes under 601.12(f)(3) - Labeling changes requiring  8
submission in an annual report.
i  1
Guidance for Industry :
Changes to an Approved Application for Specified Biotechnology and
Specified Synthetic Biological Products
I. INTRODUCTION
Sections 314.70 and 601.12 of Title 21 of the Code of Federal Regulations (21 CFR 314.70 and
601.12) prescribe the requirements for the reporting to FDA of changes to the approved applications
for licensed biological products and approved drug products.
Under  601.12  and 314.70(g), a change to a product, production process, quality controls,
equipment, or facilities is required to be reported to FDA in: 1) a supplement requiring approval prior to
distribution; 2) a supplement at least 30 days prior to distribution of the product made using the change;
or 3) in an annual report, depending on its potential to have an adverse effect on the identity, strength,
quality, purity, or potency of the product as they may relate to the safety or effectiveness of the product.
Before distributing a product made using a change, the regulations require applicants to demonstrate,
through appropriate validation and/or other clinical or non-clinical laboratory studies, the lack of adverse
effect of the change on the identity, strength, quality, purity, or potency of the product as they may relate
to its safety or effectiveness.
The three reporting categories for changes to an approved application are defined in  601.12 and 
314.70(g): 1) those changes that have a substantial potential to have an adverse effect on the identity,
strength, quality, purity, or potency of the product as they may relate to the safety or effectiveness of the
product, which require submission of a supplement and approval by FDA prior to distribution of the
product made using the change;  2) changes that have a moderate potential to have an adverse effect on
the identity, strength, quality, purity, or potency of the
1 This guidance document represents FDAs current thinking on changes to an approved application for
specified biotechnology and specified synthetic biological products listed in 21 CFR 601.2(c),
recombinant DNA-derived protein/polypeptide products approved under the Federal Food, Drug, and
Cosmetic Act (FDCA) and complexes or conjugates of a drug with a monoclonal antibody approved
under the FDCA.  It does not create or confer any rights for or on any person and does not operate to
bind FDA or the public.  An alternative approach may be used if such approach satisfies the
requirements of the applicable statute, regulations, or both.  Written requests for single copies of this
document may be submitted to the Office of Communication, Training and Manufacturers Assistance
(HFM-40), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401
Rockville Pike, Rockville, MD  20852-1448.  The document may also be obtained by mail by calling
the CBER Voice Information System at 1-800-835-4709 or 301-827-1800, or by fax by calling the
FAX Information System at 1-888-CBER-FAX or 301-827-3844.  Persons with access to the
INTERNET may obtain the document using the World Wide Web (WWW) or bounce-back e-mail.
For WWW access, connect to CBER at http://www.fda.gov/cber.  To receive the document by
bounce-back e-mail, send a message to character@a1.cber.fda.gov.
1  product as they may relate to the safety or effectiveness of the product, which require submission of a
supplement to FDA at least 30 days prior to distribution of the product made using the change; and 3)
changes that have a minimal potential to have an adverse effect on the identity, strength, quality, purity,
or potency of the product as they may relate to the safety or effectiveness of the product, which are to
be described by the applicant in an annual report.  Section 314.70(g) applies only to recombinant
DNA-derived protein/polypeptide products approved under the Federal Food, Drug, and Cosmetic
Act (FDCA) and complexes or conjugates of a drug with a monoclonal antibody approved under the
FDCA.
For licensed biologics subject to  601.12, changes to a product package label, container label, and
package insert require either: (1) submission of a supplement with FDA approval needed prior to
product distribution; (2) submission of a supplement with product distribution allowed at the time of
submission of the supplement; or (3) submission of the final printed label in an annual report.  These
requirements are now harmonized fully for drugs and biologics.
Under  601.12(f)(4), changes to advertising and promotional labeling for licensed biological products
must be made in accordance with the provisions of 21 CFR 314.81(b)(3)(i), which requires the
submission to FDA of specimens of mailing pieces and any other labeling or advertising devised for
promotion of a drug product at the time of initial dissemination of the labeling, and at the time of initial
publication of the advertisement for a prescription drug product.  Mailing pieces and labeling that are
designed to contain samples of a drug product are required to be complete, except the sample of the
drug product may be omitted from the container.  Each submission to the Center for Biologics
Evaluation and Research (CBER) should be accompanied by a completed transmittal Form FDA-2567,
or, when it is made available, the revised Form FDA-2253.
This guidance applies only to specified biotechnology and specified synthetic biological products,
including recombinant DNA-derived protein/polypeptide products approved under the FDCA and
complexes or conjugates of a drug with a monoclonal antibody approved under the FDCA, or
biological products licensed under the Public Health Service (PHS) Act and outlined in
21 CFR 601.2(c).  The section on labeling applies only to licensed biological products. This guidance is
intended to assist manufacturers in determining which reporting mechanism is appropriate for a change
to an approved application for such products.
In addition to the requirements in 21 CFR 601.12 and 314.70(g), an applicant making a change to an
approved application must conform to other applicable law and regulations, including the current good
manufacturing practice (CGMP) requirements of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 351(a)(2)(B)) and applicable regulations in 21 CFR parts 210, 211, 600 through 680, and 820.
For example, manufacturers must comply with record-keeping requirements and ensure that relevant
records are readily available for examination by authorized FDA personnel during an inspection.
Under each subsection of the guidance, FDA describes a category of changes to be reported under 
601.12 and 314.70(g).  FDA also provides a listing of various changes that FDA currently believes fall
under each category.
2 II. CHANGES UNDER  601.12(b) AND 314.70(g)(1) - Changes requiring supplement
submission and approval prior to distribution of the product made using the change
(major changes).
Under 601.12(b) and 314.70(g)(1), changes to a product, production process, quality controls,
equipment, or facilities that have a substantial potential to have an adverse effect on the identity,
strength, quality, purity, or potency of the product as they may relate to its safety or effectiveness
require submission of a supplement and approval by FDA before a product made using the change is
distributed.  For a change under this category, an applicant is required to submit a supplement to the
license application that includes a detailed description of the proposed change; the products involved;
the manufacturing site(s) or area(s) affected; a description of the methods used and studies performed to
evaluate the effect of the change on the product's identity, strength, quality, purity, or potency as they
may relate to its safety or effectiveness; the data derived from those studies; relevant validation
protocols and data; and a reference list of relevant standard operating procedures (SOPs).  The
applicant must obtain approval of the supplement by FDA prior to distribution of the product made
using the change.
In FDA's experience, the following changes to a product, production process, quality controls,
equipment, or facilities have caused detrimental effects on the identity, strength, quality, purity, or
potency of products as they relate to the products safety or effectiveness even where applicants
performed validation or other studies.  FDA believes that these changes have a substantial potential to
have an adverse effect on a products identity, strength, quality, purity, or potency as they may relate to
its safety or effectiveness and that the agency's continued premarket review and approval of such
changes is currently necessary to protect the public from products whose identity, strength, quality,
purity, potency, safety, or effectiveness may be compromised.
1.  Process changes including, but not limited to,
 extension of culture growth time leading to significant increase in number of cell
doublings beyond validated parameters;
 new or revised recovery procedures;
 new or revised purification process, including a change in a column;
 a change in the chemistry or formulation of solutions used in processing;
 a change in the sequence of processing steps or addition, deletion, or substitution of a
process step; or
 reprocessing of a product without a previously approved reprocessing protocol.
2.   Any change in manufacturing processes or analytical methods that
 results in change(s) of specification limits or modification(s) in potency, sensitivity,
specificity, or purity;
 establishes a new analytical method;
 deletes a specification or an analytical method;
 eliminates tests from the stability protocol; or
 alters the acceptance criteria of the stability protocol.
3 3. Scale-up requiring a larger fermentor, bioreactor, and/or purification equipment (applies to
production up to the final purified bulk).
4. Change in the composition or dosage form of the product or ancillary components (e.g., new or
different excipients, carriers, or buffers).
5. New lot of, new source for, or different, in-house reference standard or reference panel (panel
member) resulting in modification of reference specifications or an alternative test method.
6.  Extension of the expiration dating period and/or a change in storage temperature,
container/closure composition, or other conditions, other than changes based on real time data
in accordance with a stability protocol in the approved application.
7.  Change of the site(s) at which manufacturing, other than testing, is performed, addition of a new
location, or contracting of a manufacturing step in the approved application, to be performed at
a separate facility.
8.  Conversion of production and related area(s) from single to multiple product manufacturing
area(s). (Addition of products to a multiple product manufacturing area could be submitted as a
Supplement - Changes Being Effected in 30 Days if there are no changes to the approved
and validated cleaning and changeover procedures and no additional containment requirements).
9. Changes in the location (room, building, etc.) of steps in the production process which could
affect contamination or cross contamination precautions.
III CHANGES UNDER  601.12(c) AND 314.70(g)(2) - Changes requiring supplement
submission at least 30 days prior to distribution of the product made using the change.
Under  601.12(c) and 314.70(g)(2), changes to a product, production process, quality controls,
equipment, or facilities that have a moderate potential to have an adverse effect on a products identity,
strength, quality, purity, or potency as they may relate to its safety or effectiveness require submission
of a supplement to FDA at least 30 days prior to distribution of the product made using the change.
The requirements for the contents of these supplements are the same as for those requiring approval
prior to distribution.
  
Some examples of changes to the product, production process, quality controls, equipment, and
facilities that FDA currently considers to have moderate potential to have an adverse effect on a
products identity, strength, quality, purity, or potency as they may relate to its safety or effectiveness
are set forth in the following list which FDA has developed based on experience gained in reviewing
submissions received in the past.
1. Addition of duplicated process chain or unit process, such as a fermentation process or
duplicated purification columns, with no change in process parameters.
2. Addition or reduction in number of pieces of equipment (e.g., centrifuges, filtration devices,
blending vessels, columns, etc.) to achieve a change in purification scale not associated with a
process change.
3. Manufacture of an additional product in a previously approved multiple product manufacturing
area using the same equipment and/or personnel, if there have been no changes to the approved
4 and validated cleaning and changeover procedures and there are no additional containment
requirements.
4. Change in the site of testing from one facility to another (e.g., from a contract lab to the
applicant; from an existing contract lab to a new contract lab; from the applicant to a
new contract lab).
5. Change in the structure of a legal entity that would require issuance of a new license(s), or
change in name of the legal entity or location that would require reissuance of the
license(s)(applies only to licensed biological products).
As described in  314.70(g)(2)(v) and 601.12(c)(5), in certain circumstances FDA may determine
that, based on experience with a particular type of change, the supplement for such change is usually
complete and provides the proper information.  Likewise, there may be particular assurances that the
proposed change has been appropriately submitted, such as when the change has been validated in
accordance with a previously approved protocol.  In these circumstances, FDA may determine that the
product made using the change may be distributed at the time of receipt of the supplement by FDA.
The following are changes that in FDA's experience have been submitted properly with the appropriate
information, and could be implemented under  314.70(g)(2)(v) and 601.12(c)(5) at the time of
receipt of the supplement by FDA without a previously approved comparability protocol.
1. Addition of release tests and/or specifications or tightening of specifications for
intermediates.
2. Minor changes in fermentation batch size using the same equipment and resulting in no change in
specifications of the bulk or final product.
In addition, applicants that use the protocol described in  314.70(g)(4) and 601.12(e)to validate a
proposed change may request that a change usually subject to supplement submission and approval
prior to distribution be reported as a change subject to supplement submission at least 30 days prior to
distribution of the product made using the change, or as a "Changes Being Effected" supplement
submission, in which event the product made using the change may be distributed immediately upon
receipt of the supplement by FDA.
IV. CHANGES UNDER  601.12(d) AND 314.70(g)(3) - Changes to be described in an
annual report (minor changes).
Under  601.12(d) and 314.70(g)(3), changes to the product, production process, quality controls,
equipment, or facilities that have minimal potential to have an adverse effect on a products identity,
strength, quality, purity, or potency as they may relate to its safety or effectiveness are required to be
documented in an annual report submitted each year within 60 days of the anniversary date of approval
of the application for a biological product and in the next annual report required under -
314.81(b)(2)(iv)(b) for drug products approved under the FDCA.  For changes under this category,
the applicant is required to submit in the annual report a list of all products involved; and a full
description of the manufacturing and controls changes including: the manufacturing site(s) or area(s)
5 involved, the date each change was made, a cross-reference to relevant validation protocol(s) and/or
SOPs, and relevant data from studies and tests performed to evaluate the effect of the change on the
identity, strength, quality, purity, or potency of the product as they may relate to the safety or
effectiveness of the product.
Some examples of changes that FDA currently considers to have minimal potential to have an adverse
effect on a products identity, strength, quality, purity, or potency as they may relate to its safety or
effectiveness are listed below.  The list is not all-inclusive but contains items that, in FDA's experience
reviewing supplements, have caused few instances in which an adverse effect on the products identity,
strength, quality, purity, or potency as they may relate to its safety or effectiveness has been observed.
1. Increase in aseptic manufacturing scale for finished product without change in equipment, e.g.,
increased number of vials filled.
2. Modifications in analytical procedures with no change in the basic test methodology or existing
release specifications provided the change is supported by validation data.
3.  Change in harvesting and/or pooling procedures which does not affect the method of
manufacture, recovery, storage conditions, sensitivity of detection of adventitious agents, or
production scale.
4.  Replacement of an in-house reference standard or reference panel (or panel member) according
to SOPs and specifications in an approved application.
5. Tightening of specifications for existing reference standards to provide greater assurance of
product purity and potency.
6. Establishment of an alternate test method for reference standards, release panels, or product
intermediates, except for release testing of intermediates licensed for further manufacture.
7. Establishment of a new Working Cell Bank derived from a previously approved Master
Cell Bank according to an SOP on file in the approved license application.
8. Change in the storage conditions of in-process intermediates, which does not affect labeling,
based on data from a stability protocol in an approved application.
9. Change in shipping conditions (e.g., temperature, packaging, or custody) based on data derived
from studies following a protocol in the approved application.
10. A change in the stability test protocol to include more stringent parameters (e.g., additional
assays or tightened specifications).
11. Addition of time points to the stability protocol.
12.  Change in the simple floor plan that does not affect production process or contamination
precautions.
13.  Trend analyses of release specification testing results for bulk drug substances and drug
products obtained since the last annual report.
V.  COMPARABILITY PROTOCOLS UNDER  601.12(e) AND 314.70(g)(4)
The comparability protocol described in  601.12(e) and 314.70(g)(4) is a supplement that establishes
the tests to be done and acceptable limits to be achieved to demonstrate the lack of adverse effect for
6 specified types of manufacturing changes on the safety and effectiveness of a product.  A new
comparability protocol, or a change to an existing one, requires approval prior to implementation
because it may result in decreased reporting requirements for the changes covered.  In general, a
decrease in reporting requirement will be one reporting tier, e.g., from supplement with distribution of
product in 30 days to annual report, or from prior approval supplement to supplement with distribution
of product in 30 days.  In some cases the decrease may be greater.  The reporting category will be
established at the time that the comparability protocol is approved.  FDA intends to issue further
guidance on the use of such protocols in the near future.
VI. CHANGES UNDER  601.12(f) - Labeling changes.
This section applies only to licensed biological products.  Under  601.12(f), changes to labeling are
required to be submitted to CBER in one of the following ways: (1) As a supplement requiring FDA
approval prior to distribution of a product with the labeling change; (2) as a supplement requiring FDA
approval but permitting distribution of a product bearing such change prior to FDA approval; or (3) in
an annual report.  Some examples of changes to labeling that CBER currently considers to be
appropriate for submission in each of these three categories are listed below.  These lists are not
intended to be comprehensive.  Pursuant to  601.12(f)(4), promotional labeling and advertising must
be submitted to CBER at the time of initial dissemination or publication.
A. Changes under 601.12(f)(1) - Labeling changes requiring supplement
submission - FDA approval must be obtained before distribution of a product
with the labeling change.
Under  601.12(f)(1), any proposed change in the package insert, package label, or container
label, except those described in  601.12(f)(2) and (3), is required to be submitted as a
supplement and receive FDA approval prior to distribution of a product with the label change.
In such a supplement, the applicant is required to present clearly the proposed change in the
label and the information necessary to support the proposed change.  The following list contains
some examples of changes that are currently considered by CBER to fall into this reporting
category.
1. Changes based on postmarketing study results, including, but not limited to, labeling
changes associated with new indications and usage.
2. Change in, or addition of, pharmacoeconomic claims based on clinical studies.
3. Changes to the clinical pharmacology or the clinical study section reflecting new or
modified data.
4. Changes based on data from preclinical studies.
5. Revision (expansion or contraction) of population based on data.
6. Claims of superiority to another product.
7 B. Changes under  601.12(f)(2) - Labeling changes requiring supplement
submission - product with a labeling change that may be distributed before FDA
approval.
Under  601.12(f)(2), a supplement is required to be submitted for any change to a package
insert, package label, or container label that adds or strengthens a contraindication, warning,
precaution, or adverse reaction; adds or strengthens a statement about abuse, dependence,
psychological effect, or overdosage; adds or strengthens an instruction about dosage and
administration that is intended to increase the safety of the use of the product; or deletes false,
misleading, or unsupported indications for use or claims for effectiveness.  The applicant may
distribute product with a label bearing such a change at the time the supplement is submitted,
although the supplement is still subject to approval by FDA.  The following list includes some
examples of changes that are currently considered by FDA to fall into this reporting category.
1. Addition of an adverse event due to information reported to the applicant or Agency.
2. Addition of a precaution arising out of a post-marketing study.
3. Clarification of the administration statement to ensure proper administration of the
product.
C. Changes under  601.12(f)(3) - Labeling changes requiring submission in an
annual report.
Under  601.12(f)(3), a package insert, package label, or container label with editorial or
similar minor changes or with a change in the information on how the drug is supplied that does
not involve a change in the dosage strength or dosage form is required to be described in an
annual report.  Some examples that are currently considered by FDA to fall into this reporting
category include:
1. Changes in the layout of the package or container label without a change in content of
the labeling.
2. Editorial changes such as adding a distributors name.
3.  Foreign language versions of the labeling, if no change is made to the content of the
approved labeling and a certified translation is included.
8